EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Medical University of Vienna
Viena, AustriaPublicaciones en colaboración con investigadores/as de Medical University of Vienna (10)
2022
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
2021
-
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Annals of Oncology, Vol. 32, Núm. 10, pp. 1216-1235
-
Expected medium- And long-term impact of the COVID-19 outbreak in oncology
JCO Global Oncology, Vol. 7, pp. 162-172
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
2019
-
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project
Cancer Chemotherapy and Pharmacology, Vol. 83, Núm. 2, pp. 301-318
-
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Oncology, Vol. 20, Núm. 9, pp. 1226-1238
2018
2017
-
De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712